Schoemaker, N.E., Kuppens, I.E.L.M., Moiseyenko, V., Glimelius, B., Kjaer, M., Starkhammer, H., Richel, D.J., Smaaland, R., Bertelsen, K., Poulsen, J.P., Voznyi, E., Norum, J., Fennelly, D., Tveit, K.M., Garin, A., Gruia, G., Mourier, A., Sibaud, D., Lefebvre, P., Beijnen, J.H., Schellens, J.H. and Bokkel-Huinink, W.W. (2004) A ran- domisedphase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectalcancer. British Journal of Cancer, 91, 1434- 1441

has been cited by the following article:

• TITLE: Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer

  AUTHORS: Barbara Vandendriessche, Filip Geurs, Ingeborg Hilderson

  KEYWORDS: Colorectal; Elderly; Irinotecan; Second-Line; Unresectable

  JOURNAL NAME: Modern Chemotherapy, Vol.1 No.2, October 15, 2012

  ABSTRACT: Aims and Background: Irinotecan is a standard option for relapsed/refractory advanced colo- rectal cancer. Combination with raltitrexed and irinotecan at lower than MTD doses should preserve disease stabilisation while decreasing toxicity. Patients and Methods: From January 2004 to April 2009, we analyzed, retrospectively, our data on irinotecan + raltitrexed, fixed doses, as a second-line chemotherapy in elderly pa- tients (>70 years) with advanced colorectal can- cer after failure of oxaliplatin based chemothera- py twenty-three patients were evaluated. Iri- notecan 350 mg + raltitrexed 2.6 mg were given every 3 weeks. Tumo r measurements were ob- tained after every third course of therapy. Toxic- ity was assessed weekly using the National Cancer Institute Common Toxicity Criteria, ver- sion 2. Results: The median number of treatment courses received per patient was 4 (range, 1 - 8). All pa-tients were assessable for toxicity and 21 for response. The most frequently observed severetoxicities were diarrhea (grade 2, 13%) No cases of significant neutropenia occurred. Ob- jective partial responses were observed in 3 pa- tients (13%). An additional 10 patients (43%) had stable disease as their best response. To date, 12 patients have progressed with a median time- to-progression of 4.3 months and a median sur- vival of 8.3 months. Conclusions: A three weekly irinotecan + raltitrexed administration can indu- ce tumor control in elderly patients with advanc- ed colorectalcancer that has progressed during or shortly after oxaliplatin-based chemotherapy. The diarrhea by irinotecan, seems mitigated by coad-ministration of a smaller dose of raltitrexed